API
< Back to all clusters
[BUSINESS] · Switzerland, United States · 3 sources

started · updated

Windward Bio raises $251.2 million in Nasdaq IPO

Windward Bio Group AG has completed its initial public offering and a concurrent private placement on the Nasdaq Global Select Market, raising gross proceeds of approximately $251.2 million. The company sold 11,838,234 common shares at $17.00 each, which included the full exercise of underwriters’ options.

A significant portion of the funding, $50 million, came from a concurrent private placement by Sanofi Foreign Participations B.V. The Basel-based biotechnology company, founded in 2024 by Luca Santarelli, focuses on developing ultra-long-acting antibody medicines for respiratory and dermatologic diseases, such as asthma, COPD, and atopic dermatitis.

Windward Bio intends to use the proceeds to fund clinical trials for its lead candidates, WIN378 and WIN027. WIN378 is currently being evaluated in Phase 2/3 asthma and Phase 2 COPD studies, with the goal of providing twice-yearly dosing compared to current monthly treatments. Following its market debut, the company reached a market capitalization of approximately $1.69 billion.

Entities

Basel · Luca Santarelli · Nasdaq · Sanofi · Windward Bio Group AG